N1-Methylpseudouridine-5'-Triphosphate - (N-1081)
N1-Methylpseudouridine-5'-Triphosphate (N1MePsU) is a modified NTP for incorporation into messenger RNAs (mRNA) using an enzyme such as T7 RNA Polymerase. Modified uridines such as N1-methylpseudouridine, 5-methoxyuridine, and pseudouridine can reduce unwanted immunogenic response and enhance translational efficiency of mRNAs. These properties can result in safer mRNA and increased protein expression.
TriLink offers both research-use-only (RUO) and good manufacturing practice (GMP) N1MePsU. TriLink’s GMP rNTPs are manufactured in highly controlled environments with documented procedures, traceability of materials and processes, and strict quality control measures, providing exceptional consistency, purity, and safety.
Analytical procedures performed on TriLink’s nucleotides for quality assurance include:
TriLink’s N1MePsU is provided 100 mM in H2O, pH 7.5. To learn more about additional modified nucleotides, please visit https://www.trilinkbiotech.com/modified-nucleotides
| Catalog No | N-1081 |
|---|---|
| Purity | ≥99% by AX-HPLC |
| Extinction Coefficient | 8,877 Lmol-1cm-1 at 271 nm |
| Molecular Formula | C10H17N2O15P3 (free acid) |
| Molecular Weight | 498.10 g/mole (free acid) |
| Salt Form | Na+ |
| Concentration | 100 mM |
| Buffer | H2O |
| Recommended Storage | -20°C or below |
| Other Name(s) | N1-Methylpseudouridine-5'-Triphosphate, N1meΨTP, m1ΨTP, 1-Methyl-PseudoUridine Phosphoramidite, N1-Methyl-Pseudouridine-5'-Triphosphate |
| Application | In vitro Transcription |
| Backbone | 5'-Triphosphate |
| Base Analog(s) | Pseudouridine |
| Sugar Type(s) | RNA |
| Nucleotide Category | Base Modified RNA |
Safety Data Sheet Look-up
A nucleoside contains only the base and the sugar (5'-OH) while a nucleotide refers to a nucleoside with phosphorylation on the sugar. This includes the phosphate groups on the 2', 3' or 5' ends.
We provide custom chemistry services. Please inquire about the feasibility of your desired nucleotide at trilinkbiotech.com/custom-chemistry-services.
They are resuspended in water, pH 7.5±0.5.
A 1 µmole vial of 100 mM NTP contains 10 µL.
In general, we recommend equimolar amounts of nucleotides in IVT. The exact amounts depend on the IVT reagents and conditions. Please see our rNTP product inserts for IVT with CleanCap M6 and CleanCap AU analogs.
Yes, it can. Our product inserts have recommended ratios for small-scale IVT. If you would like to discuss it further, please contact us at trilinkbiotech.com/contact-us or [email protected].
When stored properly at or below -20°C, NTPs should be stable for a few years. Upon first use, prepare aliquots to minimize freeze-thaw cycles and NTP degradation.
Although NTPs are stable at room temperature for several days, they are shipped on wet or dry ice to ensure stability in the event of a transportation delay. Even if they have arrived thawed, they should still be good to use. If you have concerns or questions however, please contact us at trilinkbiotech.com/contact-us or [email protected].
Each NTP is accompanied by a certificate of analysis with the methods of analysis, concentration, purity, identity, etc. Our GMP NTPs undergo further analyses for characterization, safety, and nuclease contamination.
We run 31P NMR, which reveals inorganic phosphate salt. Enzymologists usually have the most concern about this salt since it inhibits many polymerases.
CoA search tool
Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission from TriLink No license under any patent or other intellectual property right of TriLink or its licensors is granted or implied by the purchase unless otherwise provided in writing.
TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.
-
Ribonucleoside-5'-Triphosphate Set with N1-Methylpseudo-UTPRibonucleoside-5'-Triphosphate Set with N1-Methylpseudo-UTP
Starting at $3,275.00
-
Ribonucleoside-5'-Triphosphate Set with 5-Methoxy-UTPRibonucleoside-5'-Triphosphate Set with 5-Methoxy-UTP
Starting at $3,275.00
-
Ribonucleoside-5'-Triphosphate Set with Pseudo-UTPRibonucleoside-5'-Triphosphate Set with Pseudo-UTP
Starting at $3,275.00
-
-
- Pardi, Norbert; Tuyishime, Steven; Muramatsu, Hiromi; Kariko, Katalin; Mui, Barbara L.; Tam, Ying K.; Madden, Thomas D.; Hope, Michael J.; Weissman, Drew . Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.
- Pardi, Norbert; Parkhouse, Kaela; Kirkpatrick, Ericka; McMahon, Meagan; Zost, Seth J.; Mui, Barbara L.; Tam, Ying K.; Karikó, Katalin; Barbosa, Christopher J.; Madden, Thomas D.; Hope, Michael J.; Krammer, Florian; Hensley, Scott E.; Weissman, Drew . Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies.
- Tiwari, Pooja Munnilal; Vanover, Daryll; Lindsay, Kevin E.; Bawage, Swapnil Subhash; Kirschman, Jonathan L.; Bhosle, Sushma; Lifland, Aaron W.; Zurla, Chiara; Santangelo, Philip J. . Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection.
- Laczk . A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice
- Lockhart, JH;VanWye, J;Banerjee, R;Wickline, SA;Pan, H;Totary-Jain, H; . Self-assembled miRNA-switch nanoparticles target denuded regions and prevent restenosis
- Leppek, K;Byeon, GW;Kladwang, W;Wayment-Steele, HK;Kerr, CH;Xu, AF;Kim, DS;Topkar, VV;Choe, C;Rothschild, D;Tiu, GC;Wellington-Oguri, R;Fujii, K;Sharma, E;Watkins, AM;Nicol, JJ;Romano, J;Tunguz, B;Participants, E;Barna, M;Das, R; . Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics
- Chen, PJ;Hussmann, JA;Yan, J;Knipping, F;Ravisankar, P;Chen, PF;Chen, C;Nelson, JW;Newby, GA;Sahin, M;Osborn, MJ;Weissman, JS;Adamson, B;Liu, DR; . Enhanced prime editing systems by manipulating cellular determinants of editing outcomes
- Everton, E;Rizvi, F;Smith, AR;Beattie, M;Tam, Y;Pardi, N;Weissman, D;Gouon-Evans, V; . Transient yet Robust Expression of Proteins in the Mouse Liver via Intravenous Injection of Lipid Nanoparticle-encapsulated Nucleoside-modified mRNA
- Appelberg, S;John, L;Pardi, N;V . Nucleoside-modified mRNA vaccines protect IFNAR-/- mice against Crimean Congo hemorrhagic fever virus infection
- Matias, J;Kurokawa, C;Sajid, A;Narasimhan, S;Arora, G;Diktas, H;Lynn, GE;DePonte, K;Pardi, N;Valenzuela, JG;Weissman, D;Fikrig, E; . Tick immunity using mRNA, DNA and protein-based Salp14 delivery strategies
- Svitkin, YV;Gingras, AC;Sonenberg, N; . Membrane-dependent relief of translation elongation
- Parhiz, H;Brenner, JS;Patel, P;Papp, TE;Shahnawaz, H;Li, Q;Shi, R;Zamora, M;Yadegari, A;Marcos-Contreras, OA;Natesan, A;Pardi, N;Shuvaev, VV;Kiseleva, R;Myerson, J;Uhler, T;Riley, RS;Han, X;Mitchell, MJ;Lam, K;Heyes, J;Weissman, D;Muzykantov, V; . Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)
- Whitley, J;Zwolinski, C;Denis, C;Maughan, M;Hayles, L;Clarke, D;Snare, M;Liao, H;Chiou, S;Marmura, T;Zoeller, H;Hudson, B;Peart, J;Johnson, M;Karlsson, A;Wang, Y;Nagle, C;Harris, C;Tonkin, D;Fraser, S;Capiz, L;Zeno, CL;Meli, Y;Martik, D;Ozaki, DA;Caparoni, A;Dickens, JE;Weissman, D;Saunders, KO;Haynes, BF;Sempowski, GD;Denny, TN;Johnson, MR; . Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials
- Aditham, A;Shi, H;Guo, J;Zeng, H;Zhou, Y;Wade, SD;Huang, J;Liu, J;Wang, X; . Chemically Modified mocRNAs for Highly Efficient Protein Expression in Mammalian Cells
- Ge, N;Sun, J;Liu, Z;Shu, J;Yan, H;Kou, Z;Wei, Y;Jin, X; . An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses
- Liu, W;Alameh, MG;Yang, JF;Xu, JR;Lin, PJC;Tam, YK; . Lipid nanoparticles delivering constitutively active STING mRNA as a novel anti-cancer therapeutic approach
- Kaur, K;Hadas, Y;Kurian, AA;?ak, MM;Yoo, J;Mahmood, A;Girard, H;Komargodski, R;Io, T;Santini, MP;Sultana, N;Kabir Sharkar, MT;Magadum, A;Fargnoli, A;Yoon, S;Chepurko, E;Chepurko, V;Eliyahu, E;Pinto, D;Lebeche, D;Kovacic, JC;Hajjar, RJ;Rafii, S;Zangi, L; . Direct Reprogramming Induces Vascular Regeneration Post Muscle Ischemic Injury
- Nakanishi, H;Saito, H; . Purification of Specific Cell Populations Differentiated from Stem Cells Using MicroRNA-Responsive Synthetic Messenger RNAs
